Economic evaluation of ceftibuten in the treatment of uncomplicated urinary tract infections in adult Mexican patients

Q4 Medicine

Revista mexicana de urologia Pub Date : 2016-01-01 DOI:10.1016/j.uromx.2015.11.002

A. Reyes-López , V. Blandón-Vijil

{"title":"Economic evaluation of ceftibuten in the treatment of uncomplicated urinary tract infections in adult Mexican patients","authors":"A. Reyes-López , V. Blandón-Vijil","doi":"10.1016/j.uromx.2015.11.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Urinary tract infections are a leading cause of medical consultations in Mexico and the growth of antimicrobial resistance results in increased morbidity and rising costs.</p></div><div><h3>Aim</h3><p>To make an economic evaluation of ceftibuten as treatment for uncomplicated urinary tract infections in adults, from the perspective of the Mexican private health system.</p></div><div><h3>Methods</h3><p>A cohort-based decision-making model was developed to compare ceftibuten with TMP-SMX, ciprofloxacin, and cefalexin. Effectiveness was measured using local susceptibility rates of <em>Escherichia coli</em>. Costs were obtained from official market value data and converted to 2014 USD values. Incremental analysis was employed to determine if ceftibuten was a worthwhile investment on the part of the private health system in Mexico.</p></div><div><h3>Results</h3><p>The total expected cost per patient for ciprofloxacin was $116 USD and the corresponding costs for TMP/SMX and cefalexin were $92.40 USD and $74.80 USD, respectively. Ceftibuten had a lower expected cost ($34.50 USD) and a higher percentage of therapeutic success (99.4%), compared with ciprofloxacin 21%, cefalexin 41%, and TMP/SMX 31.7%.</p></div><div><h3>Conclusions</h3><p>Even though ceftibuten has a higher market price than other antimicrobials in Mexico, it can represent possible savings by avoiding the costs associated with undesirable results due to antimicrobial resistance to <em>E. coli</em>.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2015.11.002","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408515001421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background

Urinary tract infections are a leading cause of medical consultations in Mexico and the growth of antimicrobial resistance results in increased morbidity and rising costs.

Aim

To make an economic evaluation of ceftibuten as treatment for uncomplicated urinary tract infections in adults, from the perspective of the Mexican private health system.

Methods

A cohort-based decision-making model was developed to compare ceftibuten with TMP-SMX, ciprofloxacin, and cefalexin. Effectiveness was measured using local susceptibility rates of Escherichia coli. Costs were obtained from official market value data and converted to 2014 USD values. Incremental analysis was employed to determine if ceftibuten was a worthwhile investment on the part of the private health system in Mexico.

Results

The total expected cost per patient for ciprofloxacin was $116 USD and the corresponding costs for TMP/SMX and cefalexin were $92.40 USD and $74.80 USD, respectively. Ceftibuten had a lower expected cost ($34.50 USD) and a higher percentage of therapeutic success (99.4%), compared with ciprofloxacin 21%, cefalexin 41%, and TMP/SMX 31.7%.

Conclusions

Even though ceftibuten has a higher market price than other antimicrobials in Mexico, it can represent possible savings by avoiding the costs associated with undesirable results due to antimicrobial resistance to E. coli.

查看原文本刊更多论文

头孢布烯治疗墨西哥成人无并发症尿路感染的经济评价

尿路感染是墨西哥医疗咨询的主要原因，抗菌素耐药性的增长导致发病率上升和成本上升。目的从墨西哥私立卫生系统的角度对头孢布烯治疗成人无并发症尿路感染进行经济评价。方法建立基于队列的决策模型，将头孢布烯与TMP-SMX、环丙沙星、头孢氨苄进行比较。使用当地大肠杆菌的敏感性来衡量有效性。成本来自官方市场价值数据，并转换为2014年美元价值。采用增量分析来确定头孢布酮对墨西哥私人卫生系统的部分投资是否值得。结果环丙沙星的预期总成本为116美元/例，TMP/SMX和头孢氨苄的预期总成本分别为92.40美元和74.80美元/例。与环丙沙星21%、头孢氨苄41%和TMP/SMX 31.7%相比，头孢布烯的预期成本更低(34.50美元)，治疗成功率更高(99.4%)。结论尽管头孢布烯在墨西哥的市场价格高于其他抗菌素，但它可以避免因大肠杆菌耐药而导致的不良后果，从而节省成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista mexicana de urologia Medicine-Urology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.